Connor Clark & Lunn Investment Management Ltd. Raises Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 88.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 871,527 shares of the company’s stock after purchasing an additional 409,357 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 1.23% of Ventyx Biosciences worth $1,909,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. LMR Partners LLP purchased a new position in Ventyx Biosciences in the 3rd quarter valued at approximately $218,000. Intech Investment Management LLC acquired a new stake in shares of Ventyx Biosciences in the third quarter valued at $42,000. Charles Schwab Investment Management Inc. raised its stake in shares of Ventyx Biosciences by 3.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock valued at $1,058,000 after acquiring an additional 17,898 shares in the last quarter. Sio Capital Management LLC boosted its holdings in Ventyx Biosciences by 153.2% in the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the period. Finally, Vestal Point Capital LP increased its holdings in Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after purchasing an additional 410,000 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Down 2.8 %

Shares of VTYX opened at $1.37 on Wednesday. The firm’s fifty day simple moving average is $1.76 and its 200-day simple moving average is $2.09. The firm has a market capitalization of $97.45 million, a price-to-earnings ratio of -0.58 and a beta of 0.58. Ventyx Biosciences, Inc. has a twelve month low of $1.33 and a twelve month high of $8.02.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.13. On average, analysts predict that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Insider Transactions at Ventyx Biosciences

In other news, Director Sheila Gujrathi bought 130,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now owns 130,000 shares of the company’s stock, valued at approximately $300,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Nuss sold 13,161 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the sale, the insider now directly owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 18.18% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.